华领医药：商业化快速放量，迈向全球价值兑现的关键阶段

格隆汇08-20

华领医药发布2026年上半年未经审核综合业绩。报告期内，公司核心产品全球首创抗糖尿病新药、葡萄糖激酶激活剂(GKA)华堂宁®(多格列艾汀片)自主商业化进入规模化放量阶段，并在中国香港和中国澳门市场获批实现商业化落地。截至2026年6月底，华堂宁®销量约305.5万盒，相较2025年同期，同比增长73%，实现营收约3.789亿元，同比增长74%。利润方面，公司盈利能力大幅优化，规模效应充分释放...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2660282324?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-20 20:49","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2660282324","market":"hk","top_or_hot":-1,"title":"华领医药：商业化快速放量，迈向全球价值兑现的关键阶段","media":"格隆汇","content":"<div>\n<p>华领医药发布2026年上半年未经审核综合业绩。\n报告期内，公司核心产品全球首创抗糖尿病新药、葡萄糖激酶激活剂(GKA)华堂宁®(多格列艾汀片)自主商业化进入规模化放量阶段，并在中国香港和中国澳门市场获批实现商业化落地。\n截至2026年6月底，华堂宁®销量约305.5万盒，相较2025年同期，同比增长73%，实现营收约3.789亿元，同比增长74%。\n利润方面，公司盈利能力大幅优化，规模效应充分释放...</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">网页链接</a>\n\n</div>\n","source":"live_gelonghui","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>华领医药：商业化快速放量，迈向全球价值兑现的关键阶段</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n华领医药：商业化快速放量，迈向全球价值兑现的关键阶段\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-20 20:49 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/rss/live/live.xml><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>华领医药发布2026年上半年未经审核综合业绩。\n报告期内，公司核心产品全球首创抗糖尿病新药、葡萄糖激酶激活剂(GKA)华堂宁®(多格列艾汀片)自主商业化进入规模化放量阶段，并在中国香港和中国澳门市场获批实现商业化落地。\n截至2026年6月底，华堂宁®销量约305.5万盒，相较2025年同期，同比增长73%，实现营收约3.789亿元，同比增长74%。\n利润方面，公司盈利能力大幅优化，规模效应充分释放...</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02552","symbol_name":"华领医药-B","start_time":0,"source_url":"https://www.gelonghui.com/rss/live/live.xml","article_id":"2660282324","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2660282324","pubTimestamp":1787230191,"columns":[],"sourceInfo":{"source_id":"live_gelonghui","name":"格隆汇"},"weMediaInfo":null,"summary":"华领医药发布2026年上半年未经审核综合业绩。\n报告期内，公司核心产品全球首创抗糖尿病新药、葡萄糖激酶激活剂(GKA)华堂宁®(多格列艾汀片)自主商业化进入规模化放量阶段，并在中国香港和中国澳门市场获","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02552":"华领医药-B","BK1574":"生物医药B类股","BK1191":"制药"},"translate_title":"Hualing Pharmaceuticals: Rapid volume of commercialization, moving towards a critical stage of global value realization","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02552":1.5},"content_text":"华领医药发布2026年上半年未经审核综合业绩。\n报告期内，公司核心产品全球首创抗糖尿病新药、葡萄糖激酶激活剂(GKA)华堂宁®(多格列艾汀片)自主商业化进入规模化放量阶段，并在中国香港和中国澳门市场获批实现商业化落地。\n截至2026年6月底，华堂宁®销量约305.5万盒，相较2025年同期，同比增长73%，实现营收约3.789亿元，同比增长74%。\n利润方面，公司盈利能力大幅优化，规模效应充分释放，毛利率突破60%。按毛利扣除销售及分销费用口径计算，2026年上半年商业化板块盈利达1.074亿元，较2025年同期实现翻倍增长，自主商业化盈利能力持续兑现。\n此外，公司银行结余及现金约人民币10.729亿元，资金状况保持稳健。\n华领医药创始人、CEO陈力博士表示：“2026年上半年，是华领医药从源头创新走向市场价值兑现的关键阶段。面向未来，公司将坚持以血糖稳态调控为根基，推进新一代长效GKA、固定复方制剂和联合用药的糖尿病稳态治疗新格局，构建覆盖疾病预防、特殊糖尿病、脂肪肝和脂肪性肝炎、认知障碍和衰弱症等的人体能量代谢健康管线矩阵，运用人工智能技术持续拓宽血糖稳态技术平台的临床边界和应用场景，推动中国原创新药惠及海内外广大代谢疾病患者。”","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2660282324","isCrawlerRequest":true}